Carriage of the HLA class II allele group HLA-DQA1*05 is associated with an increased risk of immunogenicity to infliximab and adalimumab in patients with inflammatory bowel disease (IBD).2 This evidence concerns the gene HLA-DQA1 and inflammatory bowel disease.